Death · patients on maintenance HD with CRBSI
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Death (any cause) ( · heart failure with chronic kidney disease
It is very uncertain whether CHRONIC: Aldosterone antagonists changes death (any cause) ( compared with placebo (very low certainty).
1 finding from 1 review
Cardiovascular mortality · heart failure with chronic kidney disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Death at one year · adults with renal vasculitis
The intervention showed no clear difference in death at one year (low certainty).
1 finding from 1 review
Death · patients on HD with HCV infection
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Death · patients on HD with HCV infection
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Death (all causes) · preventing bone disease in kidney transplant recipients
It is very uncertain whether vitamin D changes death (all causes) compared with placebo or no treatment (very low certainty).
1 finding from 1 review
Death (all causes) · preventing bone disease in kidney transplant recipients
It is very uncertain whether bisphosphonate changes death (all causes) compared with placebo or no treatment (very low certainty).
1 finding from 1 review
Cardiovascular mortality · preventing bone disease in kidney transplant recipients
It is very uncertain whether vitamin D changes cardiovascular death compared with placebo or no treatment (very low certainty).
1 finding from 1 review
Cardiovascular mortality · preventing bone disease in kidney transplant recipients
It is very uncertain whether bisphosphonate changes cardiovascular death compared with placebo or no treatment (very low certainty).
1 finding from 1 review
Adverse events: death · minimal change disease in adults with nephrotic syndrome
Mycophenolate sodium + oral steroids showed no clear difference in adverse events: death compared with oral steroids alone (low certainty).
1 finding from 1 review
CKD or death: death by 52 weeks · idiopathic steroid‐resistant nephrotic syndrome in children
Cyclosporin showed no clear difference in CKD or death: death by 52 weeks compared with mycophenolate mofetil with pulse dexamethasone (low certainty).
1 finding from 1 review
Adverse events: death (all causes) · idiopathic steroid‐resistant nephrotic syndrome in children
Oral cyclophosphamide showed no clear difference in adverse events: death (all causes) compared with prednisone or placebo (low certainty).
1 finding from 1 review
CKD or death: 50% decline in GFR by 78 weeks · idiopathic steroid‐resistant nephrotic syndrome in children
Cyclosporin showed no clear difference in CKD or death: 50% decline in GFR by 78 weeks compared with mycophenolate mofetil with pulse dexamethasone (low certainty).
1 finding from 1 review